<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396043</url>
  </required_header>
  <id_info>
    <org_study_id>LBL-308</org_study_id>
    <nct_id>NCT02396043</nct_id>
  </id_info>
  <brief_title>Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma</brief_title>
  <official_title>Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma
      (T-LBL) according to modified BFM-95 regimen for acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients received a modified BFM regimen which was derived from the NHL-BFM-95. Th e diff
      erences were as follows: (1) during the course of high-dose methotrexate therapy (HD-MTX),
      citrovorum folinate (CF) was used for rescue at 36 h after the administration of HD-MTX;(2)
      cranial prophylactic radiotherapy was omitted, but all patients received regular intrathecal
      chemotherapy and four additional HD-MTX treatments during maintenance therapy.(3) Pirarubicin
      was used instead of daunorubicin (4) Pegaspargase was used instead of L- asparaginase for
      patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>every 4 weeks,up to completion of induction treatment(approximately 2months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety, including hematological safety and non-hematological safety.All the adverse events will be classified according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma, Lymphoblastic</condition>
  <arm_group>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modifed BFM-95:
First patients were stratified into two therapy arms according to the disease stage. Patients with stage I or II disease received induction, protocol M and maintenance therapy. Patients with stage III or IV disease received induction, protocol M, reinduction and maintenance therapy.Maintenance therapy included oral 6-mercaptopurine (6-MP), 50 mg/m 2 daily, and MTX, 20 mg/m 2 once a week.Note that there were four additional doses of HD-MTX every 3 months during the maintenance phase. All patients received regular intrathecal chemotherapy.The treatment lasted 2.0 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction</intervention_name>
    <description>Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.
Pegaspargase :3750U/m2 im on days 8,22</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Vincristine,Pirarubicin,Prednisone,Pegaspargase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction</intervention_name>
    <description>Cyclophosphamide: 1000 mg/m2 iv on days 29, 57,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41, 45-48, 52-55,Mercaptopurine: 60 mg/m2 po on days 29-56</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Cyclophosphamide,Cytarabine,Mercaptopurine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>protocol M</intervention_name>
    <description>Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Methotrexate,Mercaptopurine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maintenance therapy</intervention_name>
    <description>6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>6-mercaptopurine,Methotrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reinduction</intervention_name>
    <description>Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.
Pegaspargase :3750U/m2 im on days 8</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Vincristine,Pirarubicin,Prednisone,Pegaspargase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reinduction</intervention_name>
    <description>Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Cyclophosphamide,Cytarabine,Mercaptopurine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal (IT)</intervention_name>
    <description>methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>methotrexate ,cytarabine and dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosedT-LBL

          -  age:18-65years

          -  Ann Arbor stage IEto stage IVE

          -  at lease one measurable lesion

          -  receive no chemotherapy or radiotherapy before

          -  Adequate renal function (eg, serum creatinine≤1.5 mg/dL and creatinine clearance ≥50
             mL minute), and hepatic function (e.g, total bilirubin≤ 2 times the upper limit of
             normal and aspartate and alanine transaminase levels ≤ 3 times the upper limit of
             normal)

        Exclusion Criteria:

          -  mismatch the inclusion criteria

          -  systematic central nervous system involvement, previous or concomitant malignancies
             and any coexisting medical problems that could cause poor compliance with the study
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Wang, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Wang, MD.</last_name>
    <phone>0086-02087342438</phone>
    <email>wanghua@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongjun Xia, MD.</last_name>
      <phone>0086-02087342438</phone>
      <email>zhongjunxia_64@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wang K, Chen X, Wuxiao Z, Wang Z, Sun X, Zeng Z, Li S, Xia ZJ. Long-term outcomes of modified Berlin-Frankfurt-Münster-90 regimen in adults with T-lymphoblastic lymphoma: a single-center experience. Leuk Lymphoma. 2014 Aug;55(8):1800-5. doi: 10.3109/10428194.2013.828350. Epub 2014 Mar 7.</citation>
    <PMID>24475787</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>wanghua</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

